亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes

医学 慢性阻塞性肺病 2型糖尿病 危险系数 内科学 糖尿病 恶化 耐受性 艾塞那肽 重症监护医学 数据库 不利影响 置信区间 内分泌学 计算机科学
作者
Avik Ray,Julie M. Paik,Deborah J. Wexler,Sushama Kattinakere Sreedhara,Katsiaryna Bykov,William B. Feldman,Elisabetta Patorno
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:185 (4): 399-399 被引量:37
标识
DOI:10.1001/jamainternmed.2024.7811
摘要

Importance: Recent studies have suggested that sodium-glucose cotransporter-2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase 4 inhibitors (DPP-4is) may benefit patients with chronic obstructive pulmonary disease (COPD). However, clinical evidence is lacking on their comparative association with COPD exacerbations in US patients with type 2 diabetes (T2D). Objective: To compare the risk of moderate or severe COPD exacerbations among SGLT-2is, GLP-1RAs, and DPP-4is. Design, Setting, and Participants: This comparative effectiveness research study used data from three 1:1 propensity score-matched cohort studies that emulated 3 target trials comparing patients 40 years or older with T2D and active COPD who initiated treatment with SGLT-2is vs DPP-4is, GLP-1RAs vs DPP-4is, and SGLT-2is vs GLP-1RAs. Data were from 3 US insurance claims databases: the Optum deidentified Clinformatics Data Mart Database (2013-2023), IBM Health MarketScan (2013-2021), and Medicare fee for service (2013-2020). The data analysis was conducted from January to June 2024. Exposures: Initiation of SGLT-2i or DPP-4i, GLP-1RA or DPP-4i, and SGLT-2i or GLP-1RA for the 3 target trials, respectively. Main Outcomes and Measures: First occurrence of a moderate or severe COPD exacerbation, defined as a filled prescription for oral glucocorticoids in association with an outpatient COPD visit or hospitalization for COPD. Incidence rates, incidence rate differences (IRDs), and hazard ratios (HRs) with 95% CIs were calculated. Results: There were 27 991, 32 107, and 36 218 pairs in the SGLT-2i vs DPP-4i, GLP-1RA vs DPP-4i, and SGLT-2i vs GLP-1RA propensity score-matched cohorts, respectively (mean [SD] age, 70.8 [8.6] and 70.7 [8.8], 70.4 [8.5] and 70.4 [8.2], and 69.8 [8.7] years, respectively; 13 767 [49.2%] and 13 847 [49.5%], 17 622 [54.9%] and 17 620 [54.9%], and 18 807 [51.9%] and 18 854 [52.1%] female individuals, respectively). During a median follow-up of 145 (IQR, 61-355) days of treatment, the risk of moderate or severe COPD exacerbation was lower among those treated with SGLT-2is vs DPP-4is (9.26 vs 11.4 per 100 person-years [PYs]; HR, 0.81; 95% CI, 0.76-0.86; IRD/100 PYs, -2.20; 95% CI, -2.83 to -1.58) and among those treated with GLP-1RAs vs DPP-4is (9.89 vs 11.49 per 100 PYs; HR, 0.86; 95% CI, 0.81-0.91; IRD/100 PYs, -1.60; 95% CI, -2.18 to -1.02), with minimal differences among those treated with SGLT-2is vs GLP-1RAs (9.47 vs 10.00 per 100 PYs; HR, 0.94; 95% CI, 0.89-1.00; IRD/100 PYs, -0.55; 95% CI, -1.09 to -0.01). Results were consistent across sensitivity and subgroup analyses. Conclusions and Relevance: The results of this comparative effectiveness research study suggest that SGLT-2is and GLP-1RAs were associated with a reduced risk of moderate or severe COPD exacerbations compared with DPP-4i in adults with T2D and active COPD. This may inform prescribing of glucose-lowering medications among patients with T2D and active COPD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
机智的白卉的应助被u102060采纳,获得10
1秒前
李健的应助被u680513采纳,获得10
3秒前
优雅谷蕊完成签到,获得积分10
7秒前
odd完成签到,获得积分10
10秒前
科研通AI6.2的应助被u102060采纳,获得10
11秒前
余凌兰完成签到 ,获得积分10
11秒前
syvshc的应助被u680513采纳,获得10
13秒前
领导范儿的应助被u855744采纳,获得10
15秒前
超级的迎梅完成签到,获得积分10
27秒前
机智的白卉的应助被u680513采纳,获得10
29秒前
科研通AI6.3的应助被u680513采纳,获得10
33秒前
小蘑菇的应助被吴彦祖采纳,获得10
37秒前
41秒前
科研通AI6.4的应助被u855744采纳,获得10
47秒前
科研通AI6.3的应助被u855744采纳,获得10
49秒前
科研通AI6.3的应助被u264877采纳,获得10
49秒前
科研通AI6.2的应助被u855744采纳,获得10
51秒前
科研通AI6.3的应助被u855744采纳,获得10
51秒前
科研通AI6.2的应助被u264877采纳,获得10
54秒前
科研通AI6.3的应助被u264877采纳,获得10
55秒前
风吹麦浪的应助被u583484采纳,获得10
55秒前
科研通AI6.3的应助被u264877采纳,获得10
59秒前
漂亮的新梅完成签到,获得积分10
1分钟前
七七完成签到 ,获得积分10
1分钟前
忧郁的数据线关注了科研通微信公众号
1分钟前
1分钟前
syvshc的应助被u721406采纳,获得10
1分钟前
u588294驳回了852的应助
1分钟前
1分钟前
1分钟前
遇上就这样吧给u266829的求助进行了留言
1分钟前
顺利手链完成签到,获得积分10
1分钟前
生动的昊焱完成签到,获得积分10
1分钟前
阿切尔代的应助被科研通管家采纳,获得10
1分钟前
1分钟前
2分钟前
吴彦祖发布了新的文献求助10
2分钟前
大胆醉卉完成签到,获得积分10
2分钟前
吴彦祖完成签到,获得积分10
2分钟前
识时务这也完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185144
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834129
捐赠科研通 7782640
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558762
邀请新用户注册赠送积分活动 2481206